Cargando…

A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH

The specific pathways, timescales, and dynamics driving the progression of fibrosis in NAFLD and NASH are not yet fully understood. Hence, a mechanistic model of the pathogenesis and treatment of fibrosis in NASH will necessarily have significant uncertainties. The rate of fibrosis progression and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Lyndsey F., Musante, Cynthia J., Allen, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261985/ https://www.ncbi.nlm.nih.gov/pubmed/37324150 http://dx.doi.org/10.3389/fmed.2023.1130890

Ejemplares similares

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Selected topics on continuous-time controlled Markov chains and Markov games /
por: Prieto-Rumeau, Tomás
Publicado: (2012)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Continuous-time Markov chains: an applications-oriented approach
por: Anderson, William J
Publicado: (1991)

Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
por: Liebig, Stephanie, et al.
Publicado: (2019)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Passage times for Markov chains
por: Syski, R, et al.
Publicado: (1992)

Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies
por: Heinemann, Fabian, et al.
Publicado: (2022)

Markov-Modulated Continuous-Time Markov Chains to Identify Site- and Branch-Specific Evolutionary Variation in BEAST
por: Baele, Guy, et al.
Publicado: (2020)

Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes
por: Carrieri, Patrizia, et al.
Publicado: (2022)

Continuous-Time Markov Chains and Applications: A Two-Time-Scale Approach
por: Yin, G George, et al.
Publicado: (2013)

Intraluminal thrombus effect on the progression of abdominal aortic aneurysms by using a multistate continuous-time Markov chain model
por: Zhang, Liangliang, et al.
Publicado: (2020)

Continuous-time markov chains and applications: a singular perturbation approach
por: Yin, G George, et al.
Publicado: (1998)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Involvement of Intracellular TAGE and the TAGE–RAGE–ROS Axis in the Onset and Progression of NAFLD/NASH
por: Sakasai-Sakai, Akiko, et al.
Publicado: (2023)

Markov chains and mixing times
por: Levin, David A, et al.
Publicado: (2017)

Markov chains and mixing times
por: Levin, David A, et al.
Publicado: (2009)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
por: Kořínková, L., et al.
Publicado: (2020)

Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
por: Türker, Fatih, et al.
Publicado: (2021)

Linear algebra, Markov chains, and queueing models
por: Meyer, Carl, et al.
Publicado: (1993)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

Study of Disease Progression and Relevant Risk Factors in Diabetic Foot Patients Using a Multistate Continuous-Time Markov Chain Model
por: Begun, Alexander, et al.
Publicado: (2016)

Comparison of methods for calculating conditional expectations of sufficient statistics for continuous time Markov chains
por: Tataru, Paula, et al.
Publicado: (2011)

Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
por: Jadhav, Kavita, et al.
Publicado: (2020)

BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH
por: Baboota, Ritesh K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ph3b3o9ja53lqi7u688tl9lodc